Endo shareholders will receive $80 million in cash and own 49.9% of the combined company. The merged firm expects $3.6 billion in 2025 revenue and $1.2 billion in adjusted EBITDA. Feel unsure ...

Fintel reports that on April 7, 2025, BWS Financial initiated coverage of Endo (OTCPK:NDOI) with a Buy recommendation. What is the Fund Sentiment? There are 98 funds or institutions reporting ...

Mallinckrodt and Endo are merging in a cash and stock deal ... will generate $3.6 billion in 2025 revenue, plus earnings of $1.2 billion. The new entity, which will be based out of Mallinckrodt ...

Net Leverage of Approximately 2.3x Expected at Close Mallinckrodt and Endo plan to combine their generic pharmaceuticals businesses and Endo's sterile injectables business after the close of the ...

Drugmaker Mallinckrodt struck a deal to buy Endo in an effort to build a diversified pharmaceuticals company with a hefty U.S. footprint. The companies said Thursday they reached a definitive ...

Mallinckrodt and Endo said they will merge through a $6.7 billion cash and stock deal creating a combined company that will be intent on bouncing back from their troubled recent histories ...

Fans recognise how much it means to Endo to be finally at a club like Liverpool aged 32, and his brother, Satoru, has now ...